Limits...
Comparison of putative circulating cancer stem cell detection between the hepatic portal system and peripheral blood in colorectal cancer patients.

Park BS, Jung SY, Kwon SM, Bae JH, Lee SM, Shin DH, Son GM - Ann Surg Treat Res (2014)

Bottom Line: On clinical study, the mean EpCAM(+)CD133(+) cell counts of 11.6/10(5) in the hepatic portal system were somewhat lower than 15.4/10(5) in peripheral vein (P = 0.241).The numbers of putative CSC were not statistically different between the detection sites of the portal vein and peripheral vein in the colon cancer patients.Therefore, we may not have benefitted by getting the cells from the hepatic portal system.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Pusan National University Yangsan Hospital, Yangsan, Korea. ; Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea.

ABSTRACT

Purpose: The present pilot study was conducted to detect putative cancer stem cell (CSC) from the hepatic portal system and peripheral blood in the colorectal cancer patients and to compare them to healthy donor and diverticulitis patients.

Methods: Laboratory study was performed to identify the expression of cell surface markers, epithelial cell adhesion molecule (EpCAM), cytokeratin (CK) 18, CK20, CD44, and CD133, on several colon cancer cell lines. Clinical pilot study was conducted to detect putative circulating CSC as EpCAM(+)CD133(+) cell in colorectal cancer (n = 10), diverticulitis (n = 5), and four healthy donors, by using flow cytometry. Blood was drawn from the hepatic portal system and peripheral vein.

Results: On laboratory study, EpCAM was expressed in whole colon cancer cell lines, and CD44 and CD133 were simultaneously expressed in 50% of the cell lines with stemness phenotype, but CK18 and CK20 were not expressed in most of the cell lines. On clinical study, the mean EpCAM(+)CD133(+) cell counts of 11.6/10(5) in the hepatic portal system were somewhat lower than 15.4/10(5) in peripheral vein (P = 0.241). As for diverticulitis patients, EpCAM(+)CD133(+) cells were also detected to have steeper dropped to near zero, after the surgery.

Conclusion: The numbers of putative CSC were not statistically different between the detection sites of the portal vein and peripheral vein in the colon cancer patients. Therefore, we may not have benefitted by getting the cells from the hepatic portal system. In addition, the CD133(+)EpCAM(+) cells in the colon cancer patients might contain normal stem cells from cancer inflammation similar to diverticulitis.

No MeSH data available.


Related in: MedlinePlus

EpCAM+CD133+ cell count according to the period of diverticulitis patients (n = 5). EpCAM, epithelial cell adhesion molecule; PBMC, peripheral blood-derived mononuclear cell; POD, postoperative day.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4217260&req=5

Figure 2: EpCAM+CD133+ cell count according to the period of diverticulitis patients (n = 5). EpCAM, epithelial cell adhesion molecule; PBMC, peripheral blood-derived mononuclear cell; POD, postoperative day.

Mentions: The box plot clearly shows the changes in CD133+EpCAM+ cell counts of the study group and the control group (Figs. 1, 2). In addition, Figs. 3 and 4 indicates the flow of the cell counts with lines. The CD133+EpCAM+ cells decreased in both group, and diverticulitis patient group showed sharper decrease over time compared to the colorectal patient group.


Comparison of putative circulating cancer stem cell detection between the hepatic portal system and peripheral blood in colorectal cancer patients.

Park BS, Jung SY, Kwon SM, Bae JH, Lee SM, Shin DH, Son GM - Ann Surg Treat Res (2014)

EpCAM+CD133+ cell count according to the period of diverticulitis patients (n = 5). EpCAM, epithelial cell adhesion molecule; PBMC, peripheral blood-derived mononuclear cell; POD, postoperative day.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4217260&req=5

Figure 2: EpCAM+CD133+ cell count according to the period of diverticulitis patients (n = 5). EpCAM, epithelial cell adhesion molecule; PBMC, peripheral blood-derived mononuclear cell; POD, postoperative day.
Mentions: The box plot clearly shows the changes in CD133+EpCAM+ cell counts of the study group and the control group (Figs. 1, 2). In addition, Figs. 3 and 4 indicates the flow of the cell counts with lines. The CD133+EpCAM+ cells decreased in both group, and diverticulitis patient group showed sharper decrease over time compared to the colorectal patient group.

Bottom Line: On clinical study, the mean EpCAM(+)CD133(+) cell counts of 11.6/10(5) in the hepatic portal system were somewhat lower than 15.4/10(5) in peripheral vein (P = 0.241).The numbers of putative CSC were not statistically different between the detection sites of the portal vein and peripheral vein in the colon cancer patients.Therefore, we may not have benefitted by getting the cells from the hepatic portal system.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Pusan National University Yangsan Hospital, Yangsan, Korea. ; Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea.

ABSTRACT

Purpose: The present pilot study was conducted to detect putative cancer stem cell (CSC) from the hepatic portal system and peripheral blood in the colorectal cancer patients and to compare them to healthy donor and diverticulitis patients.

Methods: Laboratory study was performed to identify the expression of cell surface markers, epithelial cell adhesion molecule (EpCAM), cytokeratin (CK) 18, CK20, CD44, and CD133, on several colon cancer cell lines. Clinical pilot study was conducted to detect putative circulating CSC as EpCAM(+)CD133(+) cell in colorectal cancer (n = 10), diverticulitis (n = 5), and four healthy donors, by using flow cytometry. Blood was drawn from the hepatic portal system and peripheral vein.

Results: On laboratory study, EpCAM was expressed in whole colon cancer cell lines, and CD44 and CD133 were simultaneously expressed in 50% of the cell lines with stemness phenotype, but CK18 and CK20 were not expressed in most of the cell lines. On clinical study, the mean EpCAM(+)CD133(+) cell counts of 11.6/10(5) in the hepatic portal system were somewhat lower than 15.4/10(5) in peripheral vein (P = 0.241). As for diverticulitis patients, EpCAM(+)CD133(+) cells were also detected to have steeper dropped to near zero, after the surgery.

Conclusion: The numbers of putative CSC were not statistically different between the detection sites of the portal vein and peripheral vein in the colon cancer patients. Therefore, we may not have benefitted by getting the cells from the hepatic portal system. In addition, the CD133(+)EpCAM(+) cells in the colon cancer patients might contain normal stem cells from cancer inflammation similar to diverticulitis.

No MeSH data available.


Related in: MedlinePlus